Eli Lilly also said it has filed for Food and Drug Administration approval of the daily GLP-1 pill, called orforglipron, for ...

Participants in a Phase III trial who switched to Eli Lilly’s orforglipron after 72 weeks of treatment with Wegovy or ...

Eli Lilly proved the worth of its obesity pill Thursday. A study showed patients who switched to orforglipron mostly kept the weight off.

Novo Nordisk's (DK:NOVO.B) next-gen medication is called CagriSema. It's a once-weekly shot that combines a long-acting amylin analogue and Wegovy. Clinical trials found that patients taking CagriSema ...

Novo Nordisk (whose injectable weight-loss medication Wegovy is shown here) and rival Eli Lilly are both developing a new generation of obesity drugs. Eli Lilly and Novo Nordisk - the dominant players ...

Linda Pescatello, Board of Trustees Distinguished Professor in the Department of Kinesiology (CAHNR), has established herself ...

More GLP-1s aim to enter US market as Novo Nordisk, Eli Lilly, and Pfizer advance obesity treatments with FDA filings and trials.

Do the exercises you like,' because any type will help control your blood pressure Alexandra Tran on Unsplash Linda ...

The secret to its rapid transit is in its chemistry. Ethanol, to give booze its proper name, is a tiny, agile molecule. It has a backbone of two carbon atoms and is soluble in water. It can hop over ...

Eli Lilly and Company today announced positive topline results from the ATTAIN-MAINTAIN trial. The Phase 3 study evaluated orforglipron, an investigational, once-daily oral small molecule ...

High blood pressure (hypertension) can be caused by a variety of factors, including your lifestyle, medical conditions, ...

It is a privilege to be invited to speak today at the National Hypertension Summit as we gather to advance our shared mission: improving hypertension ...